Pharma manufacturing news in brief
pharmafile | February 11, 2013 | News story | Manufacturing and Production |Â Â Almac, MeadWestvaco, Rexam, UPS, lillyÂ
A round-up of pharma manufacturing news, including facility updates from MeadWestvaco, Rexam, Almac, UPS and Kemwell Biopharma.
MeadWestvaco has said it will expand its pharmaceutical dispensing system production facility in Hemer, Germany, with a $7.5 million investment in additional cleanroom moulding and assembly capacity, as well as the introduction of a logistics system to control the flow of finished goods and components. The facility expansion will begin in early 2013 and is expected to finish by the end of the year.
Rexam has announced a second expansion of its insulin injection pen facility in La Verpillière, near Lyon in France, thanks to continued growth in demand by client Eli Lilly. The new phase of investment involves the creation of 2,400 sq. m. of cleanroom production space, which adds to around 3,000 sq. m. already dedicated to Lilly’s insulin pen product. The latest expansion comes four years after the companies first started working together and is expected to take three years and €15 million (around $20m) to complete.
Almac‘s new commercial packaging operations in Audubon, Pennsylvania, have successfully passed an inspection by the FDA, which the company said “marks the establishment of our US commercial packaging operations … for bottle, blister, wallet and vial labelling/packaging”. The firm’s US business development director – Jim McGibbon – said Almac is ready to start operations for its first client. That contract involves the packing of three commercial products – manufactured at Almac’s UK facility – into bottles and blisters.
Logistics and freight specialist UPS has expanded its network of specialist healthcare facilities in North America with five new sites in Ontario (Burlington), Kentucky (Louisville), California (Mira Loma), Georgia (Atlanta) and Nevada (Reno). The new facilities add approximately 800,000 sq. ft. to its capacity of around six million sq. ft. of distribution space, currently spread across a global network of 37 healthcare facilities. UPS’ healthcare facilities offer distribution space with temperature and humidity-controlled environments required by pharma and medical device manufacturers.
Phil Taylor
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …
